CRISPR Therapeutics
Senti Bio raises $105 million for its new programmable biology platform and cancer therapies
Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, said it has raised $105 million in a new round of financing led by the venture arm of life sciences
Mammoth Biosciences aims to be Illumina for the gene editing generation
In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material. Now, a little over 20
Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies
The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing te
China sides with Emmanulle Charpentier and Jennifer Doudna in CRISPR patent war
Continuing the patent dispute internationally, China has now given the Charpentier/Doudna side a patent to edit genes in the country. CRISPR pioneers Emmanuelle Charpentier and Jennifer Doudna lost a
CRISPR loses Nobel to tiny machines
CRISPR, the gene-editing technology revolutionizing the biotech industry, has failed to take home the Nobel prize in chemistry for the second year in a row. Instead, the award went to Jean-Pierre Sauv
Reshaping human health and changing lives through gene editing
Gene editing is going to fundamentally change our lives and how we traditionally think about health throughout the first half of the 21st century. The question isn’t "When will gene editing become a